Loading
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (3 ops.)
Latest filing published 17 Dec 2020 for Lipocine Inc.. Read the official filing
Filing timeline
BuySaleStephen A. Hill
Insider track record
Disclosed buys
2
Disclosed sells
3
Signal history
Closed purchases
Market purchases
2
Positive at T+90
50%
Median T+90
+10.2%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +20.2%Entry US$372.00 · Close at T+365 US$447.00
- +11.3%Entry US$5,580.00 · Close at T+365 US$6,210.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Stephen A. Hill: trading record in brief
Stephen A. Hill has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Cellectar Biosciences, Inc., Lipocine Inc. and Gyre Therapeutics, Inc. Between 20 April 2016 and 16 December 2020, the trades on record add up to 8 filings.
On the open market, the record shows 2 purchases worth €35k and 3 sales worth €5,561. On balance, insiders were net buyers of €29k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 2 option exercises. Since January 2020: 1 purchase and no sales on the market.
The record was last updated on 17 December 2020 with an option exercise in Lipocine Inc. The last insider purchase was made public on 8 June 2020, 2,326 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Stephen A. Hill
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations8 total
7,500 shares0Common StockSEC:0001638599-20-000978:0
18,000 shares@ US$1.08100.0% of flowCommon StockSEC:0001104659-20-070843:0
Canonical exit: 2 Sept 2020 (T+90)
939 shares@ US$2.219.6% of flowCommon StockSEC:0001144204-18-062709:0
53 shares@ US$2.210.5% of flowCommon StockSEC:0001144204-18-062709:1
190 shares@ US$10.07100.0% of flowCommon StockSEC:0001209191-18-049987:0
2,500 shares0Common StockSEC:0001638599-18-000027:0
1,250 shares@ US$3.47100.0% of flowCommon stockSEC:0001638599-18-000027:1
9,390 shares@ US$2.1248.0% of flowCommon Stock, par value $0.00001 per shareSEC:0001144204-16-095612:0
Canonical exit: 19 Jul 2016 (T+90)
8 of 8 declarations
